- Endo Inc. (OTCQX: NDOI) launches a new Spatial Computing Injection Simulator for Peyronie's disease.
- The simulator will be introduced at the American Urological Association Annual Meeting from April 26-29, 2025.
- This initiative marks Endo's second use of spatial computing for medical training.
Endo Inc. (OTCQX: NDOI) has announced the launch of a Spatial Computing Injection Simulator specifically designed to aid in the treatment of Peyronie's disease. This cutting-edge simulator offers an immersive experience by integrating physical penile models with digital content through an Apple Vision Pro application. Set to debut at the American Urological Association Annual Meeting from April 26-29, 2025, the simulator aims to enhance learning for urology specialists.
The innovative simulator provides a 20-minute training session designed to refine healthcare providers' injection techniques for XIAFLEX® (collagenase clostridium histolyticum), which is currently the only FDA-approved nonsurgical treatment available for Peyronie's disease. The session includes hands-on practice with product reconstitution, injection angles, procedural demonstrations, and post-injection process information.
This development represents Endo's second foray into utilizing spatial computing technology to create immersive learning environments for medical professionals. The company previously developed a similar simulator for hand specialists treating Dupuytren's contracture. Endo collaborated with the technology agency Lucid Dream to develop this Apple Vision Pro application.
Peyronie's disease is characterized by fibrous scar tissue development, causing curvature of the penis, affecting many men in the U.S. despite low diagnosis rates due to the condition's intimate nature. XIAFLEX® is a significant treatment option for those affected, providing a non-invasive alternative for appropriate patients.
